NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
Clinical Trials
10 trialsNCT01896271 2021-08-23
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT00085436 2018-06-26
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00003126 2017-01-04
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
Loyola University
Phase 3 Completed
NCT00276835 2015-04-10
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00100906 2013-08-16
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00278369 2013-05-22
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00328861 2012-11-05
Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00031564 2012-09-27
Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01176552 2010-08-24
Granulocyte-macrophage Colony-stimulating Factor, Interferon and Interleukin-2 as Adjuvant Treatment for Renal Cancer
Kidney Cancer Research Bureau
Phase 2 Completed